Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin

被引：34

作者：

Veeraputhiran, Muthu ^{[1
]}

Sundermeyer, Mark ^{[2
]}

机构：

[1] Abington Mem Hosp, Dept Internal Med, Abington, PA 19001 USA

[2] Abington Mem Hosp, Div Hematol & Med Oncol, Abington, PA 19001 USA

来源：

CLINICAL LUNG CANCER | 2008年 / 9卷 / 04期

关键词：

CYP3A4; drug interaction; hepatotoxicity; pravastatin;

D O I：

10.3816/CLC.2008.n.036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Erlotinib is an epidermal growth factor receptor inhibitor indicated as a second line of therapy for locally advanced and metastatic non-small-cell lung cancer after the failure of 1 previous chemotherpy. Simvastatin belongs to the statin family used to lower blood cholesterol. Drug interaction between erlotinib and statin has not been reported before. Both drugs are major substrates of the CYP3A4 enzyme in the liver. Thus, co-administration of these drugs can increase their serum levels, potentially leading to adverse effects. We report the interaction between erlotinib and simvastatin leading to rhabdomyolysis. Thus, caution is required with increasing usage of both of these drugs.

引用

页码：232 / 234

页数：3

共 9 条

[1] Development of the epidermal growth factor receptor inhibitor OSI-774 [J].

Grünwald, V ;

Hidalgo, M .

SEMINARS IN ONCOLOGY, 2003, 30 (03) :23-31

[2] Outcomes in 45 patients with statin-associated myopathy [J].

Hansen, KE ;

Hildebrand, JP ;

Ferguson, EE ;

Stein, JH .

ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (22) :2671-2676

[3] The potential for drug interactions with statin therapy in Ireland [J].

Heerey A. ;

Barry M. ;

Ryan M. ;

Kelly A. .

Irish Journal of Medical Science, 2000, 169 (3) :176-179

[4] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

[5] Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [J].

Hidalgo, M ;

Siu, LL ;

Nemunaitis, J ;

Rizzo, J ;

Hammond, LA ;

Takimoto, C ;

Eckhardt, SG ;

Tolcher, A ;

Britten, CD ;

Denis, L ;

Ferrante, K ;

Von Hoff, DD ;

Silberman, S ;

Rowinsky, EK .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3267-3279

[6] Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia [J].

O'Brien, SG ;

Meinhardt, P ;

Bond, E ;

Beck, J ;

Peng, B ;

Dutreix, C ;

Mehring, G ;

Milosavljev, S ;

Huber, C ;

Capdeville, R ;

Fischer, T .

BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1855-1859

[7] EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [J].

Pao, W ;

Miller, V ;

Zakowski, M ;

Doherty, J ;

Politi, K ;

Sarkaria, I ;

Singh, B ;

Heelan, R ;

Rusch, V ;

Fulton, L ;

Mardis, E ;

Kupfer, D ;

Wilson, R ;

Kris, M ;

Varmus, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13306-13311

[8]

Saif MW, 2007, J PANCREAS, V8, P365

[9] Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

← 1 →